How to Diagnose and Exclude Drug-Induced Liver Injury

Digestive Diseases

Volumn 33, Issue 4, 2015, Pages 472-476

  Watkins, Paul B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Hamner University of North Carolina Institute for Drug Safety Sciences   (United States)

Author keywords

Drug induced liver injury; LiverTox website; RUCAM score

Indexed keywords

AUTOANTIBODY; PARACETAMOL;

ARTICLE; DRUG OVERDOSE; HUMAN; IMMUNOASSAY; INCIDENCE; LIVER BIOPSY; LIVER INJURY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SEROLOGY; TOXIC HEPATITIS; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; FACTUAL DATABASE; LIVER; LIVER FUNCTION TEST; PATHOLOGY; PROCEDURES; RISK ASSESSMENT;

DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; LIVER FUNCTION TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84937428660     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000374091     Document Type: Article

References (18)

1. Chitturi S, Farrell GC: Drug induced liver disease; in Schiff ER, Maddrey WC, MF Sorrell (eds): Schiff's diseases of the liver, ed 11. Hoboken, Wiley-Blackwell, 2012, pp 703-782.
2. Danan G, Benichou C: Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: applications to drug-induced liver injury. J Clin Epidemiol 1993; 46: 1323-1330.
3. Rochon J, Protiva P, Seef LB, et al: Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-1183.
4. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J: Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248-255.
5. Davern TJ, Chalasani N, Fontana RJ, et al: Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141: 1665-1672.
6. Fontana RJ, Watkins PB, Bonkovsky HL, et al: Drug-induced liver injury network (DILIN) prospective study rationale, design and conduct. Drug Safety 2009; 32: 55-68.
7. Marudanayagam R, Shanmugam V, Gunson B, Mirza DF, et al: Aetiology and outcome of acute liver failure. HPB (Oxford) 2009; 11: 429-434.
8. Navarro VJ, Lucena MI: Liver injury induced by herbal and dietary supplement. Semin Liver Dis 2014; 34: 172-193.
9. Aithal GP, Rawlins MD, Day CP: Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319: 1541.
10. Chalasani N, Bjornsson E: Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138: 2246-2259.
11. Papay JI, Clines D, Rafi R, et al: Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009; 54: 84-90.
12. Hunt CM: Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology 2010; 52: 2216-2222.
13. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, Villar M, et al: Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44: 850-856.
14. Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ: LiverTox: a website on drug-induced liver injury. Hepatology 2013; 57: 873-874.
15. Urban TJ, Goldstein DB, Watkins PB: Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics 2012; 13: 735-738.
16. Lucena MI, Molokhia M, Shen Y, et al: Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-347.
17. Spraggs CF, Budde LR, Briley LP, et al: HLADQA1 02: 01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29: 667-673.
18. Daly AK, Donaldson PT, Bhatnagar P, et al: HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.